Advertisement

Cancer Causes & Control

, Volume 23, Issue 7, pp 1083–1089 | Cite as

Medical conditions and risk of adult myeloid leukemia

  • Kimberly J. Johnson
  • Cindy M. Blair
  • James M. Fink
  • James R. Cerhan
  • Michelle A. Roesler
  • Betsy A. Hirsch
  • Phuong L. Nguyen
  • Julie A. RossEmail author
Original paper

Abstract

Purpose

Although a few previous studies have reported positive associations between adult myeloid leukemia and a history of certain medical conditions, the etiology of most cases remains largely unknown. Our purpose was to examine associations between certain medical conditions and adult myeloid leukemia.

Methods

Using logistic regression, we evaluated associations between 16 self-reported medical conditions and myeloid leukemia in a case–control study of 670 cases [including 420 acute myeloid leukemia (AML) and 186 chronic myelogenous leukemia (CML)] and 701 population-based controls.

Results

We observed significant positive associations between AML and ulcerative colitis (odds ratio (OR) = 3.8; 95 % confidence interval (CI), 1.1–13) and between CML and peptic ulcer (OR = 2.0; 95% CI, 1.1–3.8). A personal cancer history increased both AML (OR = 2.6; 95% CI, 1.7–3.9) and CML (OR = 3.5; 95% CI, 2.0–5.8) risk even after excluding individuals who reported prior radiation and/or chemotherapy treatment.

Conclusion

Certain inflammatory medical conditions and a personal history of cancer, independent from therapy, are associated with an increased risk of myeloid leukemia.

Keywords

Acute myeloid leukemia Chronic myeloid leukemia Autoimmune disorders Medical conditions 

Notes

Acknowledgments

The authors acknowledged the grants from NIH T32 CA099936, R25 CA047888, R01 CA107143, and K05 CA157439.

Conflict of interest

The authors have no financial disclosures to report.

References

  1. 1.
    Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA (2009) Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 100(5):822–828PubMedCrossRefGoogle Scholar
  2. 2.
    Karlen P, Lofberg R, Brostrom O, Leijonmarck CE, Hellers G, Persson PG (1999) Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 94(4):1047–1052PubMedGoogle Scholar
  3. 3.
    Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2(12):1088–1095PubMedCrossRefGoogle Scholar
  4. 4.
    Askling J, Brandt L, Lapidus A, Karlen P, Bjorkholm M, Lofberg R et al (2005) Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54(5):617–622PubMedCrossRefGoogle Scholar
  5. 5.
    Hemminki K, Li X, Sundquist J, Sundquist K (2008) Cancer risks in ulcerative colitis patients. Int J Cancer 123(6):1417–1421PubMedCrossRefGoogle Scholar
  6. 6.
    Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR (2011) Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 29(21):2897–2903PubMedCrossRefGoogle Scholar
  7. 7.
    Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64(10):1414–1420PubMedCrossRefGoogle Scholar
  8. 8.
    Ross JA, Blair CK, Cerhan JR, Soler JT, Hirsch BA, Roesler MA et al (2011) Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia. Cancer Epidemiol Biomarkers Prev 20(8):1741–1750PubMedCrossRefGoogle Scholar
  9. 9.
    Slattery ML, Edwards SL, Caan BJ, Kerber RA, Potter JD (1995) Response rates among control subjects in case–control studies. Ann Epidemiol 5(3):245–249PubMedCrossRefGoogle Scholar
  10. 10.
    Das KK, Nishino HT, Chan AT (2010) Treatment-associated acute myeloid leukemia in a patient with Crohn’s disease on 6-mercaptopurine. Inflamm Bowel Dis 16(9):1454–1456PubMedCrossRefGoogle Scholar
  11. 11.
    Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V et al (2009) A review of human carcinogens-Part A: pharmaceuticals. Lancet Oncol 10(1):13–14PubMedCrossRefGoogle Scholar
  12. 12.
    Nguyen T, Vacek PM, O’Neill P, Colletti RB, Finette BA (2009) Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res 69(17):7004–7012PubMedCrossRefGoogle Scholar
  13. 13.
    Schmiegelow K (2011) Epidemiology of therapy-related myeloid neoplasms after treatment for pediatric acute lymphoblastic leukemia in the nordic countries. Mediterr J Hematol Infect Dis 3(1):e2011020PubMedCrossRefGoogle Scholar
  14. 14.
    Fabry TL, Sachar DB, Janowitz HD (1980) Acute myelogenous leukemia in patients with ulcerative colitis. J Clin Gastroenterol 2(3):225–227PubMedCrossRefGoogle Scholar
  15. 15.
    Karaoglu AO, Kadikoylu G, Yukselen V, Yasa MH, Bolaman Z (2004) Gastrointestinal lesions and Helicobacter pylori in patients with myeloproliferative disorders. Saudi Med J 25(12):1913–1916PubMedGoogle Scholar
  16. 16.
    Grulich AE, Vajdic CM (2005) The epidemiology of non-Hodgkin lymphoma. Pathology 37(6):409–419PubMedCrossRefGoogle Scholar
  17. 17.
    Lehtinen M, Ogmundsdottir HM, Bloigu A, Hakulinen T, Hemminki E, Gudnadottir M et al (2005) Associations between three types of maternal bacterial infection and risk of leukemia in the offspring. Am J Epidemiol 162(7):662–667PubMedCrossRefGoogle Scholar
  18. 18.
    Schottenfeld D, Fraumeni JF (2006) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, OxfordCrossRefGoogle Scholar
  19. 19.
    Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A et al (1994) Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res 137(2 Suppl):S68–S97PubMedCrossRefGoogle Scholar
  20. 20.
    Tsushima H, Iwanaga M, Miyazaki Y (2012) Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol 95(3):232–238PubMedCrossRefGoogle Scholar
  21. 21.
    Howard RA, Gilbert ES, Chen BE, Hall P, Storm H, Pukkala E et al (2007) Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat 105(3):359–368PubMedCrossRefGoogle Scholar
  22. 22.
    Wang KL, Lin LY, Chen PM, Lin HD (2005) Chronic myeloid leukemia after treatment with 131 for thyroid carcinoma. J Chin Med Assoc 68(5):230–233PubMedCrossRefGoogle Scholar
  23. 23.
    Bauduer F, Ducout L, Dastugue N, Marolleau JP (2002) Chronic myeloid leukemia as a secondary neoplasm after anti-cancer radiotherapy: a report of three cases and a brief review of the literature. Leuk Lymphoma 43(5):1057–1060PubMedGoogle Scholar
  24. 24.
    Tsuzuki M, Handa K, Yamamoto K, Hasegawa A, Yamamoto Y, Watanabe M et al (2008) Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer. Intern Med 47(19):1739–1741PubMedCrossRefGoogle Scholar
  25. 25.
    Health Pm. Ulcerative Colitis. 2011 [cited 2011 11/4/2011]Google Scholar
  26. 26.
    Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 126(6):1504–1517PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Kimberly J. Johnson
    • 1
    • 2
  • Cindy M. Blair
    • 3
  • James M. Fink
    • 4
  • James R. Cerhan
    • 5
  • Michelle A. Roesler
    • 6
  • Betsy A. Hirsch
    • 7
  • Phuong L. Nguyen
    • 8
  • Julie A. Ross
    • 6
    • 9
    Email author
  1. 1.Brown SchoolWashington University in St. LouisSt. LouisUSA
  2. 2.Department of Pediatrics, School of MedicineWashington University in St. LouisSt. LouisUSA
  3. 3.Department of Nutrition SciencesUniversity of Alabama at BirminghamBirminghamUSA
  4. 4.Department of Laboratory Medicine and PathologyHennepin Faculty AssociatesMinneapolisUSA
  5. 5.Division of Epidemiology, Department of Health Sciences ResearchMayo ClinicRochesterUSA
  6. 6.Division of Epidemiology and Clinical Research, Department of PediatricsUniversity of MinnesotaMinneapolisUSA
  7. 7.Department of Laboratory Medicine and PathologyUniversity of MinnesotaMinneapolisUSA
  8. 8.Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA
  9. 9.Masonic Cancer CenterUniversity of MinnesotaMinneapolisUSA

Personalised recommendations